Trial Profile
A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jun 2014
Price :
$35
*
At a glance
- Drugs PF 5212377 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Pfizer
- 15 Apr 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
- 01 Apr 2014 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov record.
- 14 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.